ArticleBMC research notes2009
Long-term stability of recombinant tissue plasminogen activator at -80 C.
Article in BMC research notes, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Histotripsy and Catheter-Directed Lytic: Efficacy in Highly Retracted Porcine Clots In Vitro.Ultrasound in medicine & biology · 2024Article
- Mediation of long-pulsed ultrasound enhanced microbubble recombinant tissue plasminogen activator thrombolysis in a rat model of platelet-rich thrombus.Cardiovascular diagnosis and therapy · 2024Article
- Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke.Journal of nanobiotechnology · 2024Article
- Modified Rotational Thromboelastometry Protocol Using Tissue Plasminogen Activator for Detection of Hypofibrinolysis and Hyperfibrinolysis.Methods in molecular biology (Clifton, N.J.) · 2023Article
- (More than) doubling down: Effective fibrinolysis at a reduced rt-PA dose for catheter-directed thrombolysis combined with histotripsy.PloS one · 2022Article
- Assessment of histological characteristics, imaging markers, and rt-PA susceptibility of ex vivo venous thrombi.Scientific reports · 2021Article
- Clot Degradation Under the Action of Histotripsy Bubble Activity and a Lytic Drug.IEEE transactions on ultrasonics, ferroelectrics, and frequency control · 2021Article
- An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug.Journal of visualized experiments : JoVE · 2021Article
- In Vitro Thrombolytic Efficacy of Single- and Five-Cycle Histotripsy Pulses and rt-PA.Ultrasound in medicine & biology · 2020Article
- Spectrophotometric analysis of thrombolytic activity: SATA assay.BioImpacts : BI · 2018Article
- In vitro thrombolytic efficacy of echogenic liposomes loaded with tissue plasminogen activator and octafluoropropane gas.Physics in medicine and biology · 2017Article
- Article
- Efficacy of histotripsy combined with rt-PA in vitro.Physics in medicine and biology · 2016Article
- Microfluidic manufacture of rt-PA -loaded echogenic liposomes.Biomedical microdevices · 2016Article
- Thrombolytic efficacy and enzymatic activity of rt-PA-loaded echogenic liposomes.Journal of thrombosis and thrombolysis · 2015Article
- Shaken and stirred: mechanisms of ultrasound-enhanced thrombolysis.Ultrasound in medicine & biology · 2015Article
- Individual lytic efficacy of recombinant tissue plasminogen activator in an in vitro human clot model: rate of "nonresponse".Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2013Article
- Stability of Recombinant Tissue Plasminogen Activator at -30 °C over One Year.Pharmaceuticals (Basel, Switzerland) · 2013Article
- Temperature affects thrombolytic efficacy using rt-PA and eptifibatide, an in vitro study.Therapeutic hypothermia and temperature management · 2012Article
- Short-term high-dose effect of lovastatin on thrombolysis by rt-PA in a human whole-blood in vitro clot model.Current neurovascular research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundRecombinant tissue plasminogen activator (tPA) is a thrombolytic widely used clinically in the treatment of acute thrombotic disease such as ischemic stroke, myocardial infarction, and deep venous thrombosis. This has led to much interest in tPA based lytic therapies leading to laboratory based in-vitro and in-vivo investigations using this drug. However, tPA reconstituted in solution exhibits full activity for only 6-8 hours, according to the manufacturer. Therefore, methods to store reconstituted tPA for long durations while maintaining activity would be of assistance to laboratories using this enzyme.
findingsIn this work, the enzymatic activity of tPA stored at -80 C over time was measured, using an ELISA technique that measured the amount of active tPA bound to plasminogen activator inhibitor 1 (PAI-1) in a given sample. Sample of tPA solution mixed to a concentration of 1 (mg/ml) were stored in cryogenic vials at -80 C for up to 7 years. For a given sample, aliquots were assayed for tPA activity, and compared with a tPA standard to determine relative enzymatic activity. Results are reported as means with standard errors, and 12 measurements were performed for each sample age.
conclusionThere was no decrease in tPA activity for samples stored up to 7 years. Such cryogenic storage is a viable method for the preservation of tPA solution for laboratory investigations of tPA-based lytic therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.